PTC Therapeutics (FRA:BH3) Valuation Rank


FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €72.66
GF Value €30.44
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PTC Therapeutics Valuation Rank Related Terms

FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.66 is trading 138.7% above its estimated GF Value™ of €30.44.

Key valuation signals for FRA:BH3:

  • Valuation Rank:
  • GF Value™: €30.44 vs. price of €72.66 (138.7% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.66
Price
€30.44
GF Value